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Objective. To analyse and compare the results obtained from acute mesenteric venous thrombosis (MVT) patients before
and after the change of the clinical management principle, to assess the factors responsible for the recent better outcome and
determine the best management for this disease.
Materials and methods.We retrospectively reviewed 41 patients treated for acute MVTadmitted in our hospital between
1978 and 2003. Before 1995 (Group I), our policy was to perform surgery in patients with suspected acute MVT. After 1995
(Group II), we changed our policy to a medical approach when achievable. Each patient in this study was assessed for
diagnosis, initial management (operative or non-operative), mortality, duration of hospitalisation, and outcome.
Results. There were 13 in Group I, 28 in Group II. The mean duration of diagnoses made after admission was 7.3 S.D. 2.6
days for patients in Group I, and 1.5 S.D. 1.2 days for those in Group II (p , 0.01, Student’s t-test). Eleven patients
underwent operations and two patients received non-operative treatment initially in group I, the mortality was 39%; while
nine patients underwent operations and 19 patients received non-operative management in group II, the mortality was 11%
(p , 0.05). No death occurred in the patients with initial non-operative management. The mean duration of hospitalisation
was 26 S.D. 6.8 days in Group I and 12.6 S.D. 4.6 days in Group II (p , 0.01, Student’s t-test). No significant difference in
2-year survival rate between the two groups.
Conclusion. Recent improvements in imaging techniques and better understanding of the aetiology have led to a dramatic
change in the principle and policy of clinical management for acute MVT, which leads to a more favourable outcome of acute
MVT.
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Introduction
Acute mesenteric venous thrombosis (MVT) is an
uncommon form of intestinal ischaemia with high
mortality, comprising 5–15% of all cases with acute
mesenteric ischaemia.1 – 3 Due to its non-specific
abdominal symptoms, the diagnosis is often delayed,
and the disease is usually identified at laparotomy or
autopsy for most cases. The high mortality and
increasing postoperative complications usually make
its outcome very bad. However, recent improvements
in imaging techniques and an increased awareness of
the cause of MVT have facilitated its recognition,
leaving more time for non-operative management.
This has led to a dramatic change in our policy of its
initial management in which a medical approach (non-
operative therapy) is preferred. The aim of the present
study was to analyse the outcome of patients admitted
to our hospital for acute MVT in last 25-year period.
The results obtained in each of the two groups (either
before or after the change of policy) during this period
were assessed to determine the best management of
acute MVT.
Materials and Methods
We retrospectively reviewed the clinical course of 41
patients treated for acute MVT between January 1,
1978 and August 1, 2003. No patient with acute
MVT was excluded from present study. We
restricted the diagnosis of acute MVT to patients
with duration of symptoms less than 4 weeks.4
Primary MVT was defined as thrombosis of a
mesenteric vein that was not associated with any
other disease or aetiological factor, while the term
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‘Secondary MVT’ was used for patients with any
condition known to predispose them to MVT. These
conditions include portal hypertension, hypercoa-
gulable state and earlier abdominal surgery.5,6
The diagnosis of acute MVT was established either
by a positive result of an imaging study (transabdom-
inal Colour Doppler ultrasonography, selective angio-
graphy, CT, MRI) or by laparotomy.
Our departmental policy concerning the manage-
ment of patients with clinical suspicion of acute MVT
changed during the period of study, thus we divided
the patients into two groups. Before January 1995
(Group I), patients with the clinical suspicion of acute
MVT underwent an operation as a diagnostic test and
to perform treatment. In this period, when a CT scan
was accidentally performed at admission and was
used as a means of confirming the diagnosis of acute
MVT, the patients without peritoneal signs were
treated only with non-operative method (anticoagula-
tion, thrombolytic therapy). After January 1995 (Group
II), all patients with a clinical suspicion of acute MVT
underwent abdominal morphological examination
(colour duplex ultrasonography scanning, and/or CT
scan, and/or MRA) at the time of their admission to
the hospital. Once the diagnosis was confirmed, and
when the patients did not have peritoneal signs, non-
operative therapy including anticoagulation and
thrombolysis were used initially. A secondary oper-
ation was needed if non-operative treatment proved
ineffective and symptoms were getting worse (appear-
ance of peritoneal signs).
In all patients, non-operative management included
subcutaneous injection of low molecular weight
heparin (each bolus of 100 IU/kg twice daily after an
initial injection of Heparin 5000 IU) and intravenous
urokinase (4400 U/kg injected systemically over
60 min twice daily after an initial injection of
250,000 U over 15 min). Close clinical and haemody-
namic monitoring was undertaken for these patients.
When surgical management was chosen, a laparotomy
was performed. Intravenous heparin sodium (5000 IU)
was given immediately at the time when diagnosis was
confirmed during operation in Group II. The operation
included resection of necrotic small bowel (Group I
and II), or/and removal of thrombi in the superior
mesenteric vein and/or portal vein with a Fogarty
catheter. This was passed through the mesenteric veins
of necrotic small bowel. Local anticoagulation and
thrombolysis were performed through the Fogarty
catheter (urokinase 250,000 U in saline 10 ml injected
through the Fogarty catheter into the superior mesen-
teric vein and/or portal vein over ten minutes,
followed by injection of 10–20 ml heparin saline
solution (5000 U heparin in 250 ml saline once) in
Group II. After initial treatment (operative or non-
operative), anticoagulation and thrombolysis were
continued in all cases for 7–10 days in Group II
using the same protocol and dose as the description at
beginning of this paragraph. Oral anticoagulation
therapy (Warfarin Sodium, 3 mg, once daily) was
maintained for 6 months after discharge from hospital
for the patients without a thrombophilia. For those
with a thrombophilia, anticoagulation therapy was
maintained permanently. Anticoagulant treatment
with heparin was monitored by the activated partial
thromboplastin time (APTT), and two to three times of
the control APTT value was used to confirm satisfac-
tory anticoagulation.
Statistical analysis was performed using SPSS 10.0
software (Chicago, Illinois), X2 and Student’s t-test
were used as means of evaluating differences in
categorical variables. Kaplan–Meier estimates were
used as a means of assessing survival, and the log-rank
rest was used as a means of testing for differences in
survival between groups. All values were expressed as
mean and SE. Statistical significance was accepted
when the P-value was ,0.05.
Results
Acute MVT was diagnosed in 41 patients, with mean
age of 45 SE 10 years, and there were 26 men and 15
women. Thirteen patients (32%) were treated in the
first period (Group I) with mean age of 43 SE 10 years,
and there were nine men and four women. 28 (68%)
patients were treated in the last period (Group II) with
mean age of 48 SE 13 years, and there were 17 men and
11 women. The mean age and the sex ratio at
admission were similar in two groups. Ten patients
(24%) were considered to have primary MVT, while 31
patients (76%) were known to be predisposed to
conditions associated with MVT. No significant
difference was found between the ratio of primary
and second MVT in two groups (Table 1).
Table 1. Conditions associated with MVT
All patients Group I Group II
Primary (%) 10 (24) 3 (23) 7 (25)
Secondary (%) 31 (76) 10 (77) 21 (75)
Cirrhotic portal hypertension* 13 3 10
History of splenoectomy 5 3 2
Other earlier abdominal surgery 5 1 4
Hypercoagulable states 3 1 2
Hyertension 2 2
Nephrotic syndrome 2 2
Polycythemia vera 1 1
*Patients received no operation before.
J. Zhang et al.330
Eur J Vasc Endovasc Surg Vol 28, September 2004
Clinical presentations
Acute MVT presented as abdominal pain in all 41
patients (100%) (Table 2). Other symptoms included
abdominal distension (35%), diarrhoea (24%), lower
gastrointestinal bleeding (22%). Twenty-six patients
(63%) had diffuse abdominal pain. When pain was
localised, it was to the upper quadrants in five
patients, around umbilicus in seven patients and in
the lower quadrants in three patients. Mean body
temperature of patients at admission was 37.6 SE
0.2 8C. An elevated white bleed cell count was found in
11 patients (27%). Increased platelet counts were
present in four patients (9.7%). Three patients (7%)
presented with shortened prothrombin time (PT).
Elevated level of plasma fibrinogen was found in
four patients (9.7%).
Morphological examination
A CT scan was performed in 23 patients (47%) at
admission, including three patients from Group I and
20 patients from Group II (Table 3). A thrombus in the
superior mesenteric vein (SMV) was demonstrated by
means of a CT (enhanced CT or/and helical CT
angiography) scan in 22 patients (96%). Enlarged
bowel lumen, bowel wall thickening and peritoneal
effusion were found in these patients (Figs. 1 and 2).
An MRA examination was performed in three patients
in Group II, a thrombosis was identified in all of the
three patients. Colour duplex ultrasonography scan-
ning of SMV was performed in 15 patients (three
patients in Group I, 12 in Group II), and a thrombosis
in SMV was demonstrated in 11 patients (73%). Two
patients underwent selective angiography of SMV in
Group II, and a thrombosis in SMV was demonstrated
in all of the two patients.
Diagnosis
In Group I, the diagnosis of acute MVT was estab-
lished by means morphological (CT, MRI or duplex)
examination in two patients (15%) and by means of
laparotomy in 11 patients (85%). In Group II, the
diagnosis was established by means of morphological
examination in 26 patients (93%), and by means of
laparotomy in two patients (7%). The mean duration
for diagnosis after admission was 7.3 SE 2.6 days for
patients in Group I and 1.5 SE 1.2 days for patients in
Group II, t ¼ 6:56; P , 0:01:
Treatment
Of the 13 patients in Group I, 11 patients (85%)
underwent operations and two patients (15%)
received non-operative treatment initially (Table 4).
In-hospital mortality occurred in five patients. Among
these, four patients in the earlier period of Group I
died of broad bowel necrosis or total bowel necrosis
after initial operations. We consider that the main
reason for this is that postoperative anti-coagulation
and thrombolytic therapy were not used in these
patients. Another patient in Group I died of acute
myocardial infarction after operation. The two patients
in Group I who underwent non-operative treatment
recovered. Of 28 patients in Group II, nine patients
(33%) underwent operations. Among them, three
patients died of total or extensive bowel necrosis
which was identified at operation. One patient under-
went bowel resection on three occasions due to
progressive bowel necrosis, and the total length of
bowel resected was up to 4.3 m in one patient. This
patient survived and was released from hospital.
Another patient underwent a second operation and
recovered. In the remaining four patients, two under-
went thrombectomy by Fogarty catheter with intrao-
perative local anticoagulation and thrombolysis; the
other two underwent bowel resections and thrombect-
omy by Fogarty catheter with intraoperative local
anticoagulation and thrombolysis. No further oper-
ation was need in these patients who survived and
were discharged. In all, 19 patients (68%) in Group II
underwent non-operative treatment. All survived to
be discharged from hospital. Two patients among
them had reoccurrence of symptoms (abdominal pain,
abdominal distension and bloody stool) and were
managed by further thrombolysis at 1.5–2 times the
previous dose. The symptoms gradually resolved.
Outcome
Mortality rate in Group II was 11%, compared with
that of Group I (39%), P ¼ 0:033 (X2). The mean
duration of hospitalisation for initial treatment was 26
Table 2. Symptoms and signs at admission
All patients
(%)
Group I
(%)
Group II
(%)
Abdominal pain 41 (100) 13 (100) 28 (100)
Diffuse 26 (63) 9 (69) 17 (61)
Localized 15 (37) 4 (31) 11 (39)
Abdominal distention 14 (35) 5 (38) 9 (32)
Diarrhea 13 (24) 4 (31) 6 (21)
Bloody stool 9 (22) 4 (31) 5 (18)
Duration of symptoms (days) 9.2 SE 5.0 8.9 SE 5.6 9.3 SE 4.8
Peritonitis 13 (32) 6 (46) 7 (25)
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SE. 6.8 days for patients in Group I and 12.6 SE 4.6
days for Group II, t ¼ 5:68; P , 0:01: Mean follow-up
period in this study was 32 SE 1.5 months. Overall the
2-year survival rate was 74%. No death occurred in
Group I in the 2 years following discharge, while two
patients in Group II died. On death was due to late
stage cirrhosis with liver failure; another patient died
of acute multiple cerebral infarctions. No difference
was found between the two groups in their 2-year
survival rate (Table 5) (Fig. 3).
Discussion
This study describes patient outcome in a large
single centre series of patients with acute MVT. This
case series and other recent reports5,6 show that the
number of patients with primary or idiopathic MVT
has continued to decrease over last decade as our
ability to diagnose inherited thrombotic disorders
and to recognise hypercoagulable states improves.
Conversely the proportion of patients with second-
ary MVT continues to rise. Better understanding of
predisposing conditions associated with MVT has
facilitated early recognition in of MVT. Our results
show that acute secondary MVT comprises 76% of
patients in this group, in which cirrhotic portal
hypertension, splenectomy and previous abdominal
surgery are ranked as the main factors associated
with MVT. This is in contrast to reports from
western countries.1,4 – 7
An apparent increase in the incidence of acute MVT
as we have experienced recently may be due to
improved diagnostic capabilities rather than to an
actual increase in disease frequency. Widespread use
of CT, ultrasonography and MRI combined with
advances in these technologies have added greatly to
the ease of diagnosing acute MVT at an early stage.
This may explain why the mortality rates amongst our
more recent patients are lower than those from our
earlier experience and results from other centres.7 – 9
Prompt recognition of acute MVT followed by early
aggressive treatment may limit progression of the
thrombotic process. We consider full examination
(including imaging studies) for any patient with
clinical suspicion of acute MVT at admission to try to
detect and identify the possible disease as early as
possible. The change in our clinical management
originated from experience of two patients in the late
period of Group I. These patients were diagnosed as
acute MVT by incidental CT scan on admission.
Table 3. Morphological examination
All patients
(%)
Group I
(%)
Group II
(%)
Color duplex ultrasonography 15 3 (23) 12 (43)
MVT diagnosis 11 (73) 2 (66.7) 9 (75)
Bowel wall thickening 9 (60) 3 (100) 6 (50)
Peritoneal effusion 6 (40) 1 (33.3) 5 (42)
Thrombus in portal vein 5 (42)
Thrombus in splenic vein 3 (25)
CT 23 3 (23) 20 (71)
MVT diagnosis 22 (96) 2 (67) 20 (100)
Bowel wall thickening 16 (67) 3 (100) 13 (66)
Peritoneal effusion 14 (70) 2 (67) 12 (60)
Thrombus in portal vein 9 (39) 1 (33) 8 (40)
Thrombus in splenic vein 4 (17) 4 (20)
Fig. 1. Contrast material-enhanced CT image shows an
enlarged superior mesenteric vein with a filling defect in it
(arrow), which has a sharply defined wall with a rim of
increased density. Bowel dilatation, bowel wall thickening
and peritoneal effusion secondary to superior mesenteric
vein thrombosis can well be observed.
Fig. 2. Coronal reformation of three-dimensional helical CT
angiography shows a filling defect in the superior mesenteric
vein (arrow).
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However, the patients did not have peritoneal sign and
were not indicated for operation. So we used anti-
coagulation and thromblytic therapy with close
clinical monitoring. The patients gradually recovered
and finally were discharged.
Morphological examinations include CT (CTA), MRI
(MRA), colour duplex ultrasonography and selective
mesenteric angiography, among others. CT has been
shown to be the most sensitive tool for detecting acute
MVT, and it can establish the diagnosis in 90% of
patients.1,4,10 Besides conventional contrast material
enhanced CTwhich allows sensitive detection of venous
thrombosis within central large vessels of the portal-
mesenteric circulation, helical CT angiography has
become the primary diagnostic modality in our clinical
management. Magnetic resonance imaging also has
excellent sensitivity and specificity for the diagnosis of
acute MVT. Selective mesenteric angiography is
reserved for equivocal cases on non-invasive imaging
and is also used in conjunction with catheter treatment
techniques in the management of acute MVT. Colour
duplex ultrasonography allows direct evaluation of the
mesenteric and portal veins, provides semiquantitive
flow information, and allows Doppler waveform
analysis of visceral vessels. Our study shows a higher
sensitivity of colour duplex ultrasonography to acute
MVT (73%). Of 15 patients who underwent colour
duplex ultrasonography examination, 11 patients were
recognised to have acute MVT, and CT or MRA
examinations confirmed this diagnosis. An additional
three patients in this group were found to have
thrombus in the portal vein on duplex ultrasonography.
Because the patients had severe abdominal pain and
distension, acute MVT was suspected. The diagnoses
were the confirmed by CT scanning. Our clinical
experience therefore shows that colour duplex ultra-
sonography is a valuable tool in experienced hands for
the diagnosis of acute MVT. High quality ultrasound
equipment, experienced technicians and a minimum of
overlying bowel gas in the abdomen are important in
improving the early diagnosis rate.
The results presented here show that immediate
medical therapy (anti-coagulation and thrombolysis)
is beneficial to the patients on recognition of acute
MVT, and contributes to the favourable results
obtained recently in Group II. The current consensus
for acute MVT management is that patients should
receive anticoagulation treatment once the diagnosis is
established either by morphology or laparotomy.1,11,12
The high mortality rate in Group I in our study is
probably due to the lack of postoperative anti-
coagulation and thrombolytic therapy. We believe
that two patients in Group II with recurrent symptoms
during non-operative treatment were related to insuf-
ficient dosage of thrombolysis. Reports suggest that
combined thrombolytic therapy (administrated either
systemically or locally) might be more effective than
single systemic anticoagulation.13 – 15 In the light of our
clinical experience we use thrombolytic therapy as the
first-line treatment option in the non-operative man-
agement of acute MVT patients. The protocol that we
currently use is based on experience accumulated over
several years. However, it still represents an individ-
ual experience from Northeast China. The compli-
cation as bleeding following thrombolytic treatment is
rare in our series. We had two cases of haematomas
following injections, and one case with gastrointestinal
bleeding which was related to urokinase and heparin
treatment. With careful monitoring of anticoagulants
the bleeding resolved.
Our series shows that non-operative therapy is
feasible when the diagnosis is certain and when the
patient does not have peritoneal signs. Bowel infarction
without transmural necrosis is potentially reversible
Table 4. Treatment
All patients (%) Group I (%) Group II (%)
Non-operative treatment 21 (51) 2 (15) 19 (68)
Operation 20 (49) 11 (85) 9 (32)
Laparotomy 4 (10) 2 (15) 2 (7)
Bowel resection 10 (24) 9 (69) 1 (4)
Thrombectomy and intraopertive thrombolysis 2 (5) 2 (7)
Bowel resection with thrombectomy and intraoperative
thrombolysis
4 (10) 4 (14)
Table 5. Morbidity, mortality and outcome
All patients
(%)
Group I
(%)
Group II
(%)
Morbidity* 10 (24) 7 (54) 3 (11)
Pneumonia 5 (12) 3 (23) 2 (7)
Hepatic failure 3 (7) 2 (15) 1 (4)
Renal failure 2 (5) 2 (15) 0
Short bowel syndrome 2 (5) 1 (8) 1 (4)
Acute cardiac infarction 1 (2) 1 (8) 0
In-hospital mortality* 8 (20) 5 (39) 3 (11)
Hospitalization (days)* 18 SE 9.7 26 SE 6.8 13 SE 4.6
Mean follow-up (mo) 32 SE 22 55 SE 12 24 SE 18
Two-year survival (%) 74 62 79
P , 0:05ðX2Þ:
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with anticoagulation.7 Prompt recognition and early
diagnosis have allowed a substantial number of patients
to receive non-operative treatment. This factor is also
responsible for better results in recent years. Non-
operative management (Group II) has a lower mortality
rate and shorter hospital stay than that of operative
management (Group I), although their survival rates are
similar.
In summary, a change in clinical management of
acute MVT has led to a better outcome. Non-operative
management leads to reduced hospital mortality.
Careful monitoring of patients is necessary to detect
complications such as bowel necrosis and perforation
and revert operative treatment when required.
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Fig. 3. Kaplan–Meier method: Assessment of 2-year survival for patients in Group I and Group II. There was no difference in
short-term survival between the two groups, P , 0:05-(log-rank test).
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